Jörgen Elgqvist

Institution/Department: Institute of Clinical Sciences, Department ­of ­Oncology
Previous studies: University of Gothenburg
Thesis: Astatine-211 radioimmunotherapy of ovarian cancer – Therapeutic ­efficacy, myelotoxicity, and radiation dosimetry in an animal model Research areas: Radiation physics, radiobiology, nuclear medicine.
Current research: The research during the postdoc period will be focused on investigating the therapeutic efficacy of alpha-radioimmunotherapy of ­cancer. Since the research group recently has completed a phase I clinical trial in women with recurrent ovarian cancer, after second-line chemotherapy, one goal with the research is to further develop clinically feasible targeted ­therapies of the short-range high-efficiency alpha-emission from At-211, or other alpha-particle emitters, conjugated to tumor-binding ligands for application in disseminated sub-clinical residual cancer, i.e. systemic conformal radiotherapy. The research will be used to optimize the current treatment for disseminated ovarian cancer, but also to develop and test other alpha- or electronemitters conjugated to tumor-binding ligands for other malignancies. This translational research involves different studies of the therapeutic effect in vivo, studies of the biodistribution and pharmacokinetics in vivo, imaging techniques (e.g. gamma-camera imaging, light-microscopy, and electron-microscopy), radiation dosimetry (i.e. micro-, smallscale-, and classic dosimetry), computer ­modelling, and studies of the radiobiological effects in both normal and malignant cells and tumor nodules. One important issue to investigate is for example the
diffusion of antibodies into tumor nodules, for example by studying spheroids of tumor cells in vitro.

E-mail address: jorgen.elgqvist@gu.se